Johnson & Johnson Innovative Medicine company-sponsored congress materials which have been accepted for congress presentation at American Society of Hematology

First-Line Treatment in Patients With Transplant-Ineligible, Newly Diagnosed Multiple Myeloma by Age, Frailty, and Comorbidity

CARVYKTI_US-SR-10459

Tremfya Dossier Update- bottom

rybrevant dossier update - bottom

Imaavy Dossier Update- bottom

Lazcluze Dossier Update - bottom

CARVYKTI_US-SR-10545

Test-EL

Carvykti Dossier banner

Submit your medical inquiry

Contact J&J Medical Connect for your medical inquiries


This page was last modified on

Additional contact #{index}

janssenscience

Congress Materials

Payer

no-product

Dark Blue

oncology

first-line-treatment-in-patients-with-transplant-ineligible-video

Whitelist Modal

First-Line Treatment in Patients With Transplant-Ineligible, Newly Diagnosed Multiple Myeloma by Age, Frailty, and Comorbidity

Connect with us

Connect with us

Live video

Waiting for agent...

Ready to join